Navigation Links
Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial

- XIENCE V Demonstrates Superiority in Primary Endpoint of In-Segment Late Loss, Non-Inferiority in Major Secondary Endpoint of Target Vessel Failure and Superiority in Major Adverse Cardiac Events (MACE) in the SPIRIT III U.S. Trial -

ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT III U.S. pivotal clinical trial at the of Cardiology's 56th Annual Scientific Session in New Orleans demonstrated the following key results:

    --  The randomized SPIRIT III trial of 1,002 patients comparing Abbott's

        next-generation XIENCE(TM) V Everolimus Eluting Coronary Stent System

        with the TAXUS(R) paclitaxel-eluting coronary stent system met both

        its primary endpoint and major secondary endpoint.

    --  In its primary endpoint of in-segment late loss at eight months,

        XIENCE V demonstrated superiority to TAXUS with a statistically

        significant 50 percent reduction in late loss compared to TAXUS (0.14

        +/- 0.41 mm XIENCE V, 0.28 +/- 0.48 mm TAXUS, p superior =0.004).

        In-segment late loss is a measure of vessel renarrowing.

    --  In its major secondary endpoint of Target Vessel Failure at nine

        months, XIENCE V demonstrated non-inferiority to TAXUS with an

        observed 21 percent reduction in Target Vessel Failure for XIENCE V

        compared to TAXUS (7.2 percent XIENCE V, 9.0 percent TAXUS, p non-

        inferior <0.0001).  Target Vessel Failure is a measure of re-treatment

        anywhere within the target vessel and includes cardiac death or heart

        attack.

    --  Subsequent to SPIRIT III meeting its primary and major secondary

        endpoints, an analysis of nine-month Major Adverse Cardiac Events

        (MACE), such as cardiac death, heart attack or target lesion

        revascularization (artery re-treatment due to lack of blood supply),

        was undertaken in which XIENCE V demonstrated superiority to TAXUS

'"/>




Page: 1 2 3 4 5 

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work
Productivity in Patients with Rheumatoid Arthritis
2. New Analysis of Data Shows Treatment With Abbotts Humira
(Adalimumab) Significantly Reduced Disease-Related Hospitalization
for Patients with Crohns Disease
3. Abbotts Investigational Treatment ABT-874 Shows Positive Results
in Phase II Psoriasis Study
4. Abbott Announces Continued Positive Results with Xience V
Everolimus Eluting Coronary Stent in Spirit Clinical Trials
5. New Study Suggests Better Patient Outcomes with CYPHER
Sirolimus-Eluting Coronary Stent than with Taxus Stent in
Real-World Clinical Settings
6. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares
Favorably to Drug-Eluting Stents
7. Abbott Announces Positive Nine-Month Results From the Worlds First
Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial
Results at EuroPCR 2007
9. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus
Drug-Eluting Coronary Stent Systems
10. Medtronic Announces Positive Nine-Month Results for Endeavor
Resolute Next Generation Drug-Eluting Stent at EuroPCR
11. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes
for Moderate-Release Paclitaxel-Eluting Stent at Four Years
Post Your Comments:
(Date:5/17/2013)... , May 17, 2013  Orexigen® Therapeutics, Inc. (Nasdaq: ... a company overview at the UBS Global Healthcare Conference in ... for Wednesday, May 22 nd at 11 a.m. Eastern ... of the presentation, please visit the Investor Relations section of ... will be available for 14 days after the event. ...
(Date:5/17/2013)... 17, 2013  Sony Biotechnology Inc. ("Sony") today announced the ... and 130um sorting chip.  Sony will also be exhibiting its ... SH800 Cell Sorter, the EC800 flow cytometer, and new SP6800 ... 2013, which will be held at the San ... California , from May 20 - 22.  ...
(Date:5/17/2013)... -- Research explores data on treatments ...   to   be presented Shire ... global specialty biopharmaceutical company, announces that it will present ... Psychiatric Association (APA) 166th Annual Meeting in ... presented represent Shire,s ongoing commitment to the clinical research ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... Ontario, Sept. 2, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... members of its senior management team will be participating at ... and Chief Executive Officer will make a presentation at the ... London on Thursday, September 15, 2011 at 10:35 a.m. BT ...
... Lifetime Products, Inc. -- a worldwide Utah-based manufacturer ... storage sheds, and lawn and garden products -- announced ... adding a new Health and Wellness product category. ... will feature products like the award-winning Lifetime Tru-Motion™ ...
Cached Medicine Technology:Lifetime Products Enters New Product Category: Health and Wellness 2
(Date:5/20/2013)... ESMO 32nd ESTRO European Cancer Congress will take ... ), from Friday 17 September to Tuesday 1 October ... The congress will build on the success of the ... Medical Oncology) and ESTRO (European Society for Therapeutic Radiology ... in Europe to offer presentations of cutting-edge research across ...
(Date:5/20/2013)... 2013 Ariosa Diagnostics, maker of the ... syndrome and other chromosome conditions, has announced today the ... conceived or conceived using the patient’s own egg. ... analysis as an option to those women electing to ... the evaluation of fetal sex and sex chromosome genetic ...
(Date:5/20/2013)... Soliant Health, a leading specialty healthcare staffing provider ... its fifth annual Most Beautiful Hospitals in the U.S. contest. ... decided to bypass its routine selection process and include not ... be in the running for the 2013 Most Beautiful Hospitals ... and runs through June 23. Winners will be revealed on ...
(Date:5/20/2013)... Cayman, Cayman Islands (PRWEB) May 20, 2013 ... knowledge-based, high tech Special Economic Zone in the ... Referral Network, an initiative to grow the zone’s ... with Cayman’s business-friendly environment and tax benefits are ... many of them referrals from zone channel partners. ...
(Date:5/20/2013)... Jointly established by The Hong ... (Sichuan U), China's first Institute for Disaster ... officially opened. Both institutions also held the ... Reduction" to conclude lessons learnt from Wenchuan ... Margareta Wahlström, Special Representative of the Secretary-General ...
Breaking Medicine News(10 mins):Health News:Media registration for the European Cancer Congress 2Health News:Ariosa Diagnostics Expands Harmony Prenatal Test to Twin Pregnancies and Launches New X,Y Analysis Test 2Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 2Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 3Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 4Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 5Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 6Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 7Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 8Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 9Health News:Cayman Enterprise City Introduces Referral Network 2Health News:Cayman Enterprise City Introduces Referral Network 3Health News:PolyU and Sichuan U Jointly Set Up China's First Institute for Disaster Management and Reconstruction 2Health News:PolyU and Sichuan U Jointly Set Up China's First Institute for Disaster Management and Reconstruction 3
... identified a possible cause for the loss of a tumour ... development of more aggressive forms of prostate cancer. , ... prostate cancer develops because we now have some insight into ... Jeremy Squire, a professor in the Department of Pathology and ...
... HPV infection is more common among men than women, explaining ... HPV related head and neck cancer, according to a study ... by AHNS, ASCO, ASTRO and SNM., Human papillomavirus, or HPV, ... neck cancer that are becoming more prominent in the United ...
... or without chemotherapy is less effective for patients with HIV ... patients who do not have HIV, according to a study ... by AHNS, ASCO, ASTRO and SNM. , Treating head and ... Because of the advancements in treating HIV, these patients are ...
... of positron emission tomography/computed tomography (PET/CT) scans in head ... before they become clinically apparent and may improve the ... presented at the Multidisciplinary Head and Neck Cancer Symposium, ... is a relatively new test and its use as ...
... HOUSTON Scientists have connected two signature characteristics of pancreatic ... a new potential target for drugs to treat one of ... in the journal Cancer Cell and led by ... connected the molecular dots between: Mutated versions ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... developing high blood pressure, diabetes or other risk factors for ... attack or stroke by age 80 than their less healthy ... to middle age with an optimal profile, it,s really like ...
Cached Medicine News:Health News:Oral HPV infection, HPV-related cancers more common in men 2Health News:Standard treatments for head and neck cancer less effective in HIV-positive patients 2Health News:Mutated Kras spins a molecular loop that launches pancreatic cancer 2Health News:Mutated Kras spins a molecular loop that launches pancreatic cancer 3Health News:Optimal Heart Health Starts Early: Study 2Health News:Optimal Heart Health Starts Early: Study 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: